ClinicalTrials.gg
CompletedNCT06415045Updated Dec 1, 2025Results posted

A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without Food

A Phase 1 interventional study of BI 1015550 in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The main objective is to investigate the effect of food on the pharmacokinetics of BI 1015550 Formulation C2.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 50 years (inclusive)
  • (BMI) of 18.5 to 29.9 kg/m\^2 (inclusive)
  • Signed and dated written in accordance with International Conference of Harmonization-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
  • Female subject who meets the criteria defined in the protocol for a highly effective from at least 30 days before the first administration of trial medication until 7 days after last administration

Exclusion criteria

Exclusion Criteria :

  • Any finding in the medical examination (including BP, PR or ) deviating from normal and assessed as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 50 to 90 betas per minute (bpm) at screening
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance, in particular, hepatic parameters ( (ALT), Aspartate aminotransferase (AST), total ) or renal parameters (creatinine) exceeding the (ULN) at screening
  • Any evidence of a concomitant disease assessed as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders assessed as clinically relevant by the investigator
  • Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders including but not limited to depression and suicidal behavior
  • History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Nerandomilast fasted state (Reference (R))/Nerandomilast fed state Test (T)

    Nerandomilast fasted state Reference (R)/Nerandomilast fed state Test (T) Two period crossover separated by a wash-out of at least 10 days: Period 1: Participants received one 18 mg Nerandomilast Formulation C2 film-coated tablet following an overnight fast of at least 10 hours. Period 2: Participants received One 18 mg Nerandomilast Formulation C2 film-coated tablet following a high fat/high calorie meal.

    Drug: BI 1015550

  • Experimental
    Nerandomilast fed state (Test (T))/Nerandomilast fasted state (Reference (R))

    Nerandomilast fed state Test (T)/Nerandomilast fasted state Reference (R) Two period crossover separated by a wash-out of at least 10 days: Period 1: Participants received One 18 mg Nerandomilast Formulation C2 film-coated tablet following a high fat/high calorie meal. Period 2: Participants received one 18 mg Nerandomilast Formulation C2 film-coated tablet following an overnight fast of at least 10 hours.

    Drug: BI 1015550

Interventions

  • Participants received a single 18 mg Nerandomilast Formulation C2 film-coated tablet either after an overnight fast of at least 10 hours or following a high-fat, high-calorie meal.

    Also known as: Nerandomilast, JASCAYD®

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) (AUC0-tz)

    Area under the concentration-time curve of Nerandomilast in plasma over the time interval from 0 to the last quantifiable data point is presented. Geometric least square mean (adjusted geometric mean) and geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. These quantities will then be back-transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint. This model will include effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment.

    Time frame: Within 3 hours before Nerandomilast administration and at 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 3:30, 4:00, 6:00, 8:00, 11:00, 12:00, 24:00, 34:00, 48:00, 58:00, 72:00, 96:00, 120:00, and 144:00 hours after administration.

  2. Maximum Measured Concentration of Nerandomilast in Plasma (Cmax)

    Maximum measured concentration of Nerandomilast in plasma (Cmax) is presented. Geometric least square mean (adjusted geometric mean) and geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. These quantities will then be back-transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint. This model will include effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment.

    Time frame: Within 3 hours before Nerandomilast administration and at 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 3:30, 4:00, 6:00, 8:00, 11:00, 12:00, 24:00, 34:00, 48:00, 58:00, 72:00, 96:00, 120:00, and 144:00 hours after administration.

Secondary outcomes

  1. Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of Nerandomilast in plasma over the time interval from 0 extrapolated to infinity is presented. Geometric least square mean (adjusted geometric mean) and geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. These quantities will then be back-transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint. This model will include effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment.

    Time frame: Within 3 hours before Nerandomilast administration and at 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 3:30, 4:00, 6:00, 8:00, 11:00, 12:00, 24:00, 34:00, 48:00, 58:00, 72:00, 96:00, 120:00, and 144:00 hours after administration.

07

Results

Posted Dec 1, 2025

Participant flow

This open-label, single-dose, 2-period, 2-sequence crossover trial investigated how food affects the pharmacokinetics of an 18 mg nerandomilast tablet (Formulation C2). Subjects received nerandomilast in a fasting (Reference (R)) and fed (Test (T)) state with a minimum 10-day washout period in between and were randomized to the sequences R-T or T-R.

period 1
Participant flow — period 1
MilestoneNerandomilast fasted state (Reference (R))/Nerandomilast fed state Test (T)Nerandomilast fed state (Test (T))/Nerandomilast fasted state (Reference (R))
Started99
Completed99
Not completed00
Washout period
Participant flow — Washout period
MilestoneNerandomilast fasted state (Reference (R))/Nerandomilast fed state Test (T)Nerandomilast fed state (Test (T))/Nerandomilast fasted state (Reference (R))
Started99
Completed99
Not completed00
Period 2
Participant flow — Period 2
MilestoneNerandomilast fasted state (Reference (R))/Nerandomilast fed state Test (T)Nerandomilast fed state (Test (T))/Nerandomilast fasted state (Reference (R))
Started99
Completed99
Not completed00

Outcome measures

PrimaryArea Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) (AUC0-tz)

Area under the concentration-time curve of Nerandomilast in plasma over the time interval from 0 to the last quantifiable data point is presented. Geometric least square mean (adjusted geometric mean) and geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. These quantities will then be back-transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint. This model will include effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment.

Time frame:
Within 3 hours before Nerandomilast administration and at 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 3:30, 4:00, 6:00, 8:00, 11:00, 12:00, 24:00, 34:00, 48:00, 58:00, 72:00, 96:00, 120:00, and 144:00 hours after administration.
Reported as:
Geometric least squares mean · hour*nanomol/Liter (h*nmol/L)
Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) (AUC0-tz)
hour*nanomol/Liter (h*nmol/L)Nerandomilast fasted state (Reference (R))Nerandomilast fed state (Test (T))
Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point) (AUC0-tz)2225.20 ± NA2563.65 ± NA
Statistical analysis
  • Nerandomilast fasted state (Reference (R)) vs Nerandomilast fed state (Test (T)) · Ratios of adjusted geometric means [%]: 115.21 · 90% CI 106.55 to 124.58Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 13.5
PrimaryMaximum Measured Concentration of Nerandomilast in Plasma (Cmax)

Maximum measured concentration of Nerandomilast in plasma (Cmax) is presented. Geometric least square mean (adjusted geometric mean) and geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. These quantities will then be back-transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint. This model will include effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment.

Time frame:
Within 3 hours before Nerandomilast administration and at 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 3:30, 4:00, 6:00, 8:00, 11:00, 12:00, 24:00, 34:00, 48:00, 58:00, 72:00, 96:00, 120:00, and 144:00 hours after administration.
Reported as:
Geometric least squares mean · nanomol/Liter (nmol/L)
Maximum Measured Concentration of Nerandomilast in Plasma (Cmax)
nanomol/Liter (nmol/L)Nerandomilast fasted state (Reference (R))Nerandomilast fed state (Test (T))
Maximum Measured Concentration of Nerandomilast in Plasma (Cmax)412.88 ± NA354.35 ± NA
Statistical analysis
  • Nerandomilast fasted state (Reference (R)) vs Nerandomilast fed state (Test (T)) · Ratios of adjusted geometric means [%]: 85.82 · 90% CI 68.80 to 107.06Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 39.4
SecondaryArea Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of Nerandomilast in plasma over the time interval from 0 extrapolated to infinity is presented. Geometric least square mean (adjusted geometric mean) and geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model. These quantities will then be back-transformed to the original scale to provide the point estimate and 90% confidence intervals (CIs) for each endpoint. This model will include effects accounting for the following sources of variation: sequence, subjects within sequences, period and treatment.

Time frame:
Within 3 hours before Nerandomilast administration and at 0:15, 0:30, 0:45, 1:00, 1:15, 1:30, 1:45, 2:00, 2:30, 3:00, 3:30, 4:00, 6:00, 8:00, 11:00, 12:00, 24:00, 34:00, 48:00, 58:00, 72:00, 96:00, 120:00, and 144:00 hours after administration.
Reported as:
Geometric least squares mean · hour*nanomol/Liter (h*nmol/L)
Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hour*nanomol/Liter (h*nmol/L)Nerandomilast fasted state (Reference (R))Nerandomilast fed state (Test (T))
Area Under the Concentration-time Curve of Nerandomilast in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)2240.58 ± NA2578.16 ± NA
Statistical analysis
  • Nerandomilast fasted state (Reference (R)) vs Nerandomilast fed state (Test (T)) · Ratios of adjusted geometric means [%]: 115.07 · 90% CI 106.38 to 124.46Ratio calculated as test/reference\*100. Intra-individual Geometric coefficient of variation \[%\] = 13.5

Adverse events

Collected over Adverse event collection period: up to 7 days from first Nerandomilast administration. All-cause mortality: up to 28 days from first Nerandomilast administration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nerandomilast fasted state (Reference (R))0/18 (0%)0/18 (0%)8/18 (44.4%)
Nerandomilast fed state (Test (T))0/18 (0%)0/18 (0%)7/18 (38.9%)
Most frequent other events
Most frequent other events
EventNerandomilast fasted state (Reference (R))Nerandomilast fed state (Test (T))
HeadacheNervous system disorders4/185/18
FlatulenceGastrointestinal disorders1/180/18
Catheter site painGeneral disorders1/180/18
NasopharyngitisInfections and infestations1/181/18
Decreased appetiteMetabolism and nutrition disorders0/181/18
Pain in extremityMusculoskeletal and connective tissue disorders0/181/18
DizzinessNervous system disorders1/180/18
DysmenorrhoeaReproductive system and breast disorders1/180/18
Oropharyngeal painRespiratory, thoracic and mediastinal disorders1/180/18

Baseline characteristics

Treated set (TS): The treated set includes all participants who were treated with at least one dose of trial drug.

Age, Continuous
Age, Continuous(Years)Nerandomilast Fasted State (Reference (R))/Nerandomilast Fed State Test (T)Nerandomilast Fed State (Test (T))/Nerandomilast Fasted State (Reference (R))Total
Mean41.0 ± 7.138.0 ± 6.539.5 ± 6.8
Sex: Female, Male
Sex: Female, Male(Participants)Nerandomilast Fasted State (Reference (R))/Nerandomilast Fed State Test (T)Nerandomilast Fed State (Test (T))/Nerandomilast Fasted State (Reference (R))Total
Female448
Male5510
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nerandomilast Fasted State (Reference (R))/Nerandomilast Fed State Test (T)Nerandomilast Fed State (Test (T))/Nerandomilast Fasted State (Reference (R))Total
Hispanic or Latino011
Not Hispanic or Latino9817
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Nerandomilast Fasted State (Reference (R))/Nerandomilast Fed State Test (T)Nerandomilast Fed State (Test (T))/Nerandomilast Fasted State (Reference (R))Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White9918
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • CRS Clinical Research Services Berlin GmbH
    Berlin, 13627, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Jul 2024, 1 month.

Results were first posted in Dec 2025, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2024
First posted
May 16, 2024
StartActual
May 28, 2024
Primary completionActual
Jul 24, 2024
CompletionActual
Jul 24, 2024
Results first posted
Dec 1, 2025
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06415045
Responsible party
Sponsor
First posted
May 16, 2024
Start date
May 28, 2024
Primary completion
Jul 24, 2024
Completion
Jul 24, 2024
Results posted
Dec 1, 2025
Last update
Dec 1, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nerandomilast

Start the discussion